China Bestar Laboratories Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 18, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,702,494 | Method for cancer treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 10,881,621 | Sintered ferrous amino acid particles and use of the same against a virus In force · From the USPTO record | In force | From the USPTO record | |
| US 11,110,065 | Sintered ferrous amino acid particles and use of the same against a virus In force · From the USPTO record | In force | From the USPTO record | |
| US 11,141,382 | Sintered nanoparticles and use of the same against a virus In force · From the USPTO record | In force | From the USPTO record | |
| US 10,813,906 | Use of ferrous amino acid chelate to treat infection by enteropathogen and to enhance growth performance In force · From the USPTO record | In force | From the USPTO record | |
| US 12,194,015 | Composition comprising ferrous amino acid particles and method for treating or ameliorating pancreas-related disease using the same In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.